Trial intelligence / Profile preview

Circadin for sleep disturbances in children with neurodevelopmental disabilities

NL-OMON41494Phase 3Active, not recruiting

Sponsor
Neurim Pharmaceuticals
Start
Feb 2015
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in sleep disorder comparing Circadin with Placebo (2 arms). Primary endpoint: Total sleep time. Started Feb 2015; status: active, not recruiting.

02

Drugs

melatonin
03

Conditions

sleep disorder

Beyond the preview

Go deeper on NL-OMON41494.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON41494.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call